Back to School: How biopharma can reboot drug development. Access exclusive analysis here
NFLD said it plans to submit a BLA to FDA in 1H08 for PolyHeme to treat life-threatening red blood cell
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury